Smith+Nephew wins FDA nod for hip system compatible with Cori surgical robot

Smith+Nephew (NYSE: SNN)+ announced today that it received FDA 510(k) clearance for its new Catalystem primary hip system.

The London-based orthopedic giant designed the system to address the evolving demands of primary hip surgery. That includes the increased adoption of anterior approach procedures and the expanding role of ambulatory surgery centers (ASCs). The system also has compatibility with Smith+Nephew’s Cori surgical robotic platform.

Smith+Nephew said in a news release that advances in primary hip arthroplasty include a shift to a shorter, proximally filling stem. This stem offers easier preparation and insertion using the direct anterior approach. That delivers a less invasive procedure that may enable an improved range of motion and faster recovery.

Sign up for Blog Updates